Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity [Yahoo! Finance]